TY - JOUR
T1 - Asthma Remission by Age at Diagnosis and Gender in a Population-Based Study
AU - Honkamäki, Jasmin
AU - Piirilä, Päivi
AU - Hisinger-Mölkänen, Hanna
AU - Tuomisto, Leena E.
AU - Andersén, Heidi
AU - Huhtala, Heini
AU - Sovijärvi, Anssi
AU - Lindqvist, Ari
AU - Backman, Helena
AU - Lundbäck, Bo
AU - Rönmark, Eva
AU - Lehtimäki, Lauri
AU - Pallasaho, Paula
AU - Ilmarinen, Pinja
AU - Kankaanranta, Hannu
N1 - Funding Information:
This work was supported by The Foundation of Ida Montin (Kerava, Finland), Allergy Research Foundation (Helsinki, Finland), The Foundation of Väinö and Laina Kivi (Helsinki, Finland), Tampere Tuberculosis Foundation (Tampere, Finland), The Finnish Anti-Tuberculosis Association Foundation (Helsinki, Finland), The Research Foundation of the Pulmonary Diseases (Helsinki, Finland), Finnish Cultural Foundation (Helsinki, Finland), The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland), The Medical Research Fund of Seinäjoki Central Hospital (Seinäjoki, Finland), and Nummela Sanatorium Foundation (Helsinki, Finland). None of the sponsors had any involvement in the planning, execution, drafting or write-up of this study.
Funding Information:
Conflicts of interest: H. Hisinger-Mölkänen is employed by GlaxoSmithKline as a Medical Advisor. L. E. Tuomisto reports personal fees and nonfinancial support from Boehringer-Ingelheim; personal fees from AstraZeneca; and nonfinancial support from TEVA, Orion, and Chiesi. B. Lundbäck reports personal fees from GSK and Sanofi. L. Lehtimäki reports personal fees from AstraZeneca, Boehringer-Ingelheim, Chiesi, Circassia, GSK, Novartis, Orion, Sanofi, and Teva. P. Ilmarinen reports grants and personal fees from AstraZeneca ; and personal fees from Mundipharma, GlaxoSmithKline, and Novartis. H. Kankaanranta reports grants, personal fees, and nonfinancial support from AstraZeneca; personal fees and nonfinancial support from Boehringer Ingelheim and Orion ; and personal fees from Chiesi, Novartis, Mundipharma, Sanofi-Genzyme, and GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2021/5
Y1 - 2021/5
N2 - Background: Child-onset asthma is known to remit with high probability, but remission in adult-onset asthma is seemingly less frequent. Reports of the association between remission and asthma age of onset up to late adulthood are scarce. Objective: To evaluate the association between asthma remission, age at diagnosis and gender, and assess risk factors of nonremission. Methods: In 2016, a random sample of 16,000 subjects aged 20 to 69 years from Helsinki and Western Finland were sent a FinEsS questionnaire. Physician-diagnosed asthma was categorized by age at diagnosis to early- (0-11 years), intermediate- (12-39 years), and late-diagnosed (40-69 years) asthma. Asthma remission was defined by not having had asthma symptoms and not having used asthma medication in the past 12 months. Results: Totally, 8199 (51.5%) responded, and 879 reported physician-diagnosed asthma. Remission was most common in early-diagnosed (30.2%), followed by intermediate-diagnosed (17.9%), and least common in late-diagnosed asthma (5.0%) (P <.001), and the median times from diagnosis were 27, 18.5, and 10 years, respectively. In males, the corresponding remission rates were 36.7%, 20.0%, and 3.4%, and in females, 20.4%, 16.6%, and 5.9% (gender difference P <.001). In multivariable binary logistic regression analysis, significant risk factors of asthma nonremission were intermediate (odds ratio [OR] = 2.15, 95% confidence interval: 1.37-3.36) and late diagnosis (OR = 11.06, 4.82-25.37) compared with early diagnosis, chronic obstructive pulmonary disease (COPD) (OR = 5.56, 1.26-24.49), allergic rhinitis (OR = 2.28, 1.50-3.46), and family history of asthma (OR = 1.86, 1.22-2.85). Results were similar after excluding COPD. Conclusion: Remission was rare in adults diagnosed with asthma after age 40 years in both genders. Late-diagnosed asthma was the most significant independent risk factor for nonremission.
AB - Background: Child-onset asthma is known to remit with high probability, but remission in adult-onset asthma is seemingly less frequent. Reports of the association between remission and asthma age of onset up to late adulthood are scarce. Objective: To evaluate the association between asthma remission, age at diagnosis and gender, and assess risk factors of nonremission. Methods: In 2016, a random sample of 16,000 subjects aged 20 to 69 years from Helsinki and Western Finland were sent a FinEsS questionnaire. Physician-diagnosed asthma was categorized by age at diagnosis to early- (0-11 years), intermediate- (12-39 years), and late-diagnosed (40-69 years) asthma. Asthma remission was defined by not having had asthma symptoms and not having used asthma medication in the past 12 months. Results: Totally, 8199 (51.5%) responded, and 879 reported physician-diagnosed asthma. Remission was most common in early-diagnosed (30.2%), followed by intermediate-diagnosed (17.9%), and least common in late-diagnosed asthma (5.0%) (P <.001), and the median times from diagnosis were 27, 18.5, and 10 years, respectively. In males, the corresponding remission rates were 36.7%, 20.0%, and 3.4%, and in females, 20.4%, 16.6%, and 5.9% (gender difference P <.001). In multivariable binary logistic regression analysis, significant risk factors of asthma nonremission were intermediate (odds ratio [OR] = 2.15, 95% confidence interval: 1.37-3.36) and late diagnosis (OR = 11.06, 4.82-25.37) compared with early diagnosis, chronic obstructive pulmonary disease (COPD) (OR = 5.56, 1.26-24.49), allergic rhinitis (OR = 2.28, 1.50-3.46), and family history of asthma (OR = 1.86, 1.22-2.85). Results were similar after excluding COPD. Conclusion: Remission was rare in adults diagnosed with asthma after age 40 years in both genders. Late-diagnosed asthma was the most significant independent risk factor for nonremission.
KW - Adult
KW - Age of onset
KW - Asthma
KW - Early-onset
KW - Gender
KW - Late-onset
KW - Population study
KW - Remission
U2 - 10.1016/j.jaip.2020.12.015
DO - 10.1016/j.jaip.2020.12.015
M3 - Article
C2 - 33338683
AN - SCOPUS:85098857511
SN - 2213-2198
VL - 9
SP - 1950
EP - 1959
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 5
ER -